|
|
|
The Demise of Conventional LASIK? Will customized LASIK procedures replace standard treatments? BY
WILLIAM I. BOND, MD; JACK T. HOLLADAY, MD, MSEE, FACS; Customized LASIK
procedures, with their promise of tailored corneal laser treatments, will no
doubt generate a lot of interest this year. In November 2002, the FDA approved
the LADARVision system with the CustomCornea indication (Alcon Laboratories,
Inc., Fort Worth, TX) for use in customized myopic laser procedures, and other
companies expect similar approvals in 2003. Not only does customized LASIK look
promising for those LASIK candidates who have been waiting for refractive
technology to improve, but it is also exciting surgeons with its potential for
re-treating patients who were disgruntled with their initial refractive
surgeries. Cataract & Refractive Surgery Today asked a group of surgeons
whether they thought this new-and-improved procedure would unseat conventional
LASIK as king of the refractive marketplace. The desire for surgeons
to be able to say that they possess “customized” or “wavefront”
technology pervades the refractive industry and currently far outstrips our
ability to deliver concrete results to patients. There are so many treatments
currently available that we refer to as “customized,” “wavefront,”
“tailor-made,” or “individualized.” Abraham Lincoln said, “If you call
a tail a leg, how many legs does a dog have? Well, the answer is four, because
calling a tail a leg doesn’t make it a leg.” More importantly,
however, I feel that we are unsure of what we are trying to accomplish in
correcting aberrations. I remember believing that a cornea free of aberrations
was a desirable state of affairs, but that was just an assumption. Now, we are
finding that 20/10 and 20/8 vision can exist with fairly large aberrations, and
we aren’t certain what to make of that. Until we determine what the desired
refractive state really is, the great hope for customized LASIK is to be able to
address previously induced refractive surgical problems. This indication could
be a godsend for long-suffering patients and their long-suffering surgeons. Jack T. Holladay, MD,
MSEE, FACS I recognized this problem
with excimer lasers about 3 years ago, and I have since added a new algorithm to
the software of the LaserScan LSX excimer laser (LaserSight Technologies, Inc.,
Winter Park, FL) that increases the amount of laser energy to compensate for
hitting the cornea obliquely. Of the 20 patients I have treated with this new
software, all have postoperative corneas that are shaped exactly like virgin
corneas. They do not have a shrinking optical zone such as those induced by
current standard treatments, and these patients’ contrast sensitivity and
wavefront measurements are as good as those of patients who have never undergone
surgery. Moreover, these treatments were standard—not what we would normally
refer to as a customized ablation.1 Correcting the systematic
calibration errors in the lasers will produce better results than the
wavefront-guided ablations performed today. Some early studies with
wavefront treatments have demonstrated better UCVA and BCVA as compared with
standard treatments, with fewer induced higher-order aberrations. In many cases,
wavefront treatments have reduced spherical aberration in particular and
improved night vision. These are remarkable achievements, but which specific
aberrations should we eliminate? In a very interesting study presented at the
2001 AAO meeting in Orlando, Florida, Steven Schallhorn, MD, examined aviators
at the Navy’s Top Gun school in Nevada. He looked at higher-order aberrations
in individuals who had not undergone any type of refractive surgery.
Surprisingly, he found that individuals with the very best UCVA had more
higher-order aberrations than those with worse UCVA. Should we aim to leave some
higher-order aberrations on the cornea, and if so, which ones? This question
obviously warrants further study. Additionally, it has been
shown that creating a LASIK flap induces aberrations that are unpredictable.
Does this fact steer us more in the direction of surface ablation for customized
work? Perhaps, but the epithelial remodeling that occurs for months following
surface ablation creates its own constellation of aberrations. Even after LASIK,
we see substantial epithelial changes for many months. It will also be
interesting to see how lenticular changes affect the situation. In my practice,
the average patient requesting refractive surgery is 41 years old, and many
individuals are in their 50s. How will these patients fare in the long term, and
how will we deal with their residual aberrations when we extract a substantial
component of the aberration equation at the time of cataract surgery? Pupil size
is another factor that dramatically affects the wavefront profile of any given
eye. As this variable changes from moment to moment and in general shrinks with
time, how will this influence matter? Customized ablations hold
huge potential in refractive surgery. There are many patients with irregular
corneas resulting from problems with prior refractive surgeries who may benefit
substantially from this technology. Applying customized ablation to the
mainstream refractive surgery patients will require careful consideration of all
these issues. The analogy of a “made-to-measure” suit versus an
“off-the-rack” suit certainly applies, but we should bear in mind that, if
we gain or lose 5 pounds in a few years, or styles change, we can simply buy
another suit. Customized ablation is for the duration. Clinical diagnostic
wavefront analysis is teaching us that visually significant higher-order
aberrations measured preoperatively are not the norm in our refractive surgery
population. In other words, completely correcting sphere and cylinder
surgically, without inducing visually significant higher-order aberrations, will
delight nearly 100% of our refractive surgery patients. However, it is the
atypical refractive surgery patient who complains of higher-order aberrations
preoperatively, while most postoperative complaints are due to surgically
induced higher-order aberrations (ie, spherical aberration). Therefore, I feel that
wavefront-guided customized ablations will eventually supplant the phoropter-guided
LASIK procedures surgeons currently perform. The phoropter, manifest, and
cycloplegic refractions will become safety checks included in preoperative
evaluations, but they will no longer be the driving parameters of the excimer
laser treatment. However, customized ablation (ie, treating the higher-order
aberrations of an eye) will not be the typical treatment objective in the
refractive surgery population, due to the ocular demographics that show that the
number of lower-order aberrations far exceed higher-order aberrations in terms
of visual significance. Formulating treatment parameters that eliminate and
prevent the induction of higher-order aberrations remains elusive, but the
journey will be stimulating and provide us with true customized-ablation (ie,
treatment of higher-order aberrations) potential. Until our understanding
of wavefront technology improves, refined conventional refractive treatments may
actually outpace wavefront treatments for consistent, effective, and stable
refractive results. The potential of conventional treatments can be seen when
comparing the postoperative results from specific excimer platforms with the
wavefront-guided postoperative results of competing excimer laser platforms.
Prior to achieving “supervision” for virgin eyes, the refractive industry
needs to develop additional treatments to re-treat postrefractive surgery
patients who manifest suboptimal outcomes with decreased BSCVA and
decreased-quality mesopic/scotopic vision. Once refractive surgeons develop more
effective methods for treating irregular astigmatism and safer microkeratome
technology, refractive surgery’s penetration into the general population will
tremendously enhance the industry's perceived and actual safety rate. In order for
wavefront-driven excimer treatments to displace conventional LASIK, a number of
philosophic and technological hurdles must be overcome. Due to the pioneering
work of Cynthia Roberts, PhD, of Columbus, Ohio, and Dan Reinstein, MD, of
Cambridge, England, wavefront researchers have begun to comprehend the effect of
biomechanical changes in the cornea induced during the lamellar surgical portion
of LASIK. The fact that so few wavefront investigations include standardized
microkeratome variability partially demonstrates the limits of current
refractive surgery knowledge. Because wavefront treatments require micron and
submicron resolution, a greater working knowledge of the factors involved with
epithelial and stromal wound-healing responses will be critical to maximizing
successful customized ablations. Elevation-based topography data must be
incorporated into these treatments in order to provide the highest-probability
“best fit” for a customized ablation. Current excimer laser beam delivery
and tracking technology is rapidly improving, but it still lags behind what is
theoretically required to perform wavefront-driven customized ablations.
Additionally, adaptive optics, which introduce virtually any desired aberration
profile into a subject's eye, must be refined to evaluate a patient’s vision
for each controlled aberration profile. This “wavefront phoropter” or
“visual simulator” would allow surgeons to determine the exact relationships
between specific aberrations and visual quality. Despite the best designs
of current wavefront investigational trials, until the issues described
previously are rigorously developed and applied, any significant visual
improvement via customized wavefront ablations will be entirely accidental and
difficult to reproduce. Therefore, it is unlikely that in the near future
customized LASIK will unseat conventional LASIK as king of the refractive
marketplace. Jack T. Holladay, MD,
MSEE, FACS, is Clinical Professor of Ophthalmology at Baylor College of Medicine
in Houston, as well as Medical Director of LaserSight Technologies, Inc., in
Winter Park, Florida. Dr. Holladay may be reached at (713) 668-7337; docholladay@docholladay.com. James Schumer, MD, is
in private practice at Eye Surgery Consultants in Mansfield, Ohio. He holds no
financial interest in any product or technology mentioned herein. Dr. Schumer
may be reached at (419) 525-3737; schumer@revisioneyes.com. Sam Omar, MD, is
from Advanced Vision Institute in Orlando, Florida. He holds no financial
interest in any product or technology mentioned herein. Dr. Omar may be reached
at (407) 389-0800; omar_eye@yahoo.com.
|